Hernandez to lead PCORnet demonstration study on best aspirin dose to protect patients with heart disease

Friday, May 8, 2015

Adrian Hernandez, MD, MHS, associate profess or medicine (Cardiology), will lead the first randomized clinical trial conducted for PCORnet, the National Patient-Centered Clinical Research Network. 

The Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) study will assess whether low- or standard-dose aspirin is better for preventing heart attacks and stroke in patients with coronary artery disease.

“This will be one of the largest pragmatic randomized clinical trials that has the potential to have a huge impact on the outcomes of patients with heart disease,” said Dr. Hernandez. “It will also change how we conduct large clinical trials by employing novel methods to identify, recruit, and follow-up patients electronically.”

The study will be the first randomized clinical trial conducted for PCORnet, the National Patient-Centered Clinical Research Network, and will serve as a test of the network’s scope and capabilities. Hernandez is co-principal investigator of PCORnet’s Coordinating Center.

PCORnet is an innovative initiative of the Patient-Centered Outcomes Research Institute (PCORI), an independent, nonprofit organization authorized by Congress in 2010 to fund research that will provide patients, their caregivers, and clinicians with the evidence-based information needed to make better-informed healthcare decisions.

Learn more about the trial.